中国临床药理学杂志Issue(2)：147-149,3.DOI:10.13699/j.cnki.1001-6821.2016.02.017
咪喹莫特与重组人干扰素α－2b对尖锐湿疣的临床疗效及安全性评价
Clinical efficacy and safety of imiquimod cream and recombinant human interferonα-2b in the treatment of condylomata acuminata
摘要
Abstract
Objective To evaluate the clinical efficacy and safety of imi-quimod cream and recombinant human interferon α-2 b in the treatment of condylomata acuminate.Methods A total of 133 cases with condylo-mata acuminate were randomly divided into control group ( n=65 ) and experiment group ( n =68 ).Patients in control group were treated with human interferon α-2b, 4 times per day.Patients in experiment group were treated with imiquimod cream , 3 times per week , all patients were treated for 8 weeks.After treatment, the clinical efficacy, recurrence rate and incidence of adverse drug reactions were evaluated between the two groups.Results The clearance rate were 89.71%, 92.65%, 97.06%in the experiment group after treatment for 1 , 2 weeks and 1 week after 8 weeks treatment , significantly higher than those in control group , which were 50.77%,75.38%,84.62%( P<0.05 ).The recur-rence rate were 7.35% and 27.69% in experiment and control group , respectively , with statistical difference ( P<0.05 ).The incidence of ad-verse drug reactions were 4.41%(3/68) and 13.85%(9/65)in experi-ment and control group , with statistical difference ( P <0.05 ) .Conclusion Compared with interferon α-2b, imiquimod cream was ef-fective and safe in the treatment of condylomata acuminate.关键词
尖锐湿疣/重组人干扰素α-2b/咪喹莫特乳膏/复发率Key words
condylomata acuminate/recombinant human interferonα-2 b/imiquimod cream/recurrence rate分类
医药卫生引用本文复制引用
陈欢,俞新民..咪喹莫特与重组人干扰素α－2b对尖锐湿疣的临床疗效及安全性评价[J].中国临床药理学杂志,2016,(2):147-149,3.基金项目
浙江丽水市科技计划基金资助项目 （）
